Clinical Trial Update: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Zanzalintinib (XL092) in combination with AB521, and Zanzalintinib with AB521 plus Nivolumab, in participants with advanced clear cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• AB521
• Zanzalintinib (Zanzalintinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Exelixis | Conditions: Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | Phase 1 | Status: TERMINATED